4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Guillain-Barre Syndrome by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 16 ongoing clinical trials involving Guillain-Barre Syndrome
Of the 16 trials,8 trials are in Phase II
Furthermore, 3 trials are in Phase III

Number of ongoing Clinical Trials (for drugs) involving Guillain-Barre Syndrome by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Guillain-Barre Syndrome, a central nervous system indication. The largest number of ongoing clinical trials for Guillain-Barre Syndrome is conducted in Europe. Asia-Pacific and Middle East and Africa are among some of the other prominent regions engaged in Guillain-Barre Syndrome-related drug trials.

Guillain-Barre Syndrome related clinical trial sponsors

Kedrion SpA, University Medical Centre Ljubljana, Assiut University, Annexon Inc, Alexion Pharmaceuticals Inc, CSL Ltd, and Hansa Biopharma AB are among other notable clinical trial sponsors involved in Guillain-Barre Syndrome. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Guillain-Barre Syndrome

Human normal immunoglobulin (Octagam, Gamten, NewGam, Globiga, and Panzyga), Human normal immunoglobulin (Venilon/ GGS-MPA), and Human Immunoglobulin (Gammagard, Gammagard S/D, Kiovig, Subcuvia, Hyqvia, Iveegam) are among the key marketed drugs involving Guillain-Barre Syndrome.

Human normal immunoglobulin (Octagam, Gamten, NewGam, Globiga, and Panzyga) is an immune sera preparation. Human normal immunoglobulin (Octagam, Gamten, NewGam, Globiga, and Panzyga) contains mainly immunoglobulin G (IgG) with a broad spectrum of antibodies against infectious agents. It is formulated as injectable solution for intravenous route of administration. Human normal immunoglobulin (Octagam, Gamten, NewGam, Globiga, and Panzyga) is marketed for the treatment of Guillain-Barre Syndrome and several other indications including Bone Marrow Transplant Rejection, Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), Mucocutaneous Lymph Node Syndrome (Kawasaki Disease), Dermatomyositis, Chronic Lymphocytic Leukemia (CLL), Primary Immune Deficiency (PID), AIDS-Related Opportunistic Infections, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Primary Humoral Immune Deficiencies, Severe Combined Immune Deficiency (SCID), WHIM Syndrome (Warts, Hypogammaglobulinemia, Infections and Myelokathexis), and Wiskott-Aldrich Syndrome. Human normal immunoglobulin was first approved in 1996 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by several pharma giants including Octapharma AG, and Pfizer Inc.

Human Immunoglobulin (Gammagard, Gammagard S/D, Kiovig, Subcuvia, Hyqvia, Iveegam) contains broad spectrum of antibodies against infectious agents. It is formulated as solution and lyophilized powder solution for intravenous, intravascular, intramuscular and subcutaneous route of administration. Human normal immunoglobulin blocks gamma Fc receptors, preventing the binding and ingestion of phagocytes and suppressing platelet depletion. Intravenous immunoglobulin (IVIG) contains a number of different antibodies, which prevent infection by attaching to the surface of invading pathogens and aiding in their disposal before they can infect cells. Antibodies remove pathogens via complement activation, agglutination or precipitation, pathogen receptor blocking, macrophage “tagging” or neutralization (via binding) of pathogen toxins. Human Immunoglobulin (Gammagard, Gammagard S/D, Kiovig, Subcuvia, Hyqvia, Iveegam) was first approved in 1998 and is marketed globally including the US, the UK, Australia, France, Germany, and Japan by several pharma giants including Baxalta Inc, Takeda Pharmaceutical Co Ltd, and Baxter Corp.